Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIXCYTE in Moderate to Severe Chronic Kidney Disease
NCT02933827Phase 2Completed
- Sponsor
- UnicoCell Biomed Co., Ltd.
- Start
- May 2018
- Primary completion
- Apr 2019
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, open-label trial of elixcyte in chronic kidney disease (CKD) (3 arms), sponsored by UnicoCell Biomed Co., Ltd. Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs) at Week 48 and Estimated Glomerular Filtration Rate at Week 24. Started May 2018; status: completed.
02
Drugs
elixcyte
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02933827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933827.